# Sintilimab and Bevacizumab Biosimilar Combined With PLD in mTNBC

> **NCT05386524** · PHASE2 · UNKNOWN · sponsor: **Fudan University** · enrollment: 41 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** sintilimab
- **DRUG:** bevacizumab biosimilar
- **DRUG:** pegylated liposomal doxorubicin

## Key facts

- **NCT ID:** NCT05386524
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-06-15
- **Primary completion:** 2025-03-15
- **Final completion:** 2025-03-15
- **Target enrollment:** 41 (ESTIMATED)
- **Last updated:** 2023-02-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05386524

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05386524, "Sintilimab and Bevacizumab Biosimilar Combined With PLD in mTNBC". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT05386524. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*